SEC EDGARAug 12$HTFL

Farquhar John C.M. sold $639K of HTFL

Farquhar John C.M. (Chief Executive Officer) sold 22,562 shares of Heartflow, Inc. (HTFL) at $28.31 ($0.64M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Farquhar John C.M.

Published Aug 12, 2026, 9:07 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$HTFL

Neutral

medium confidence

Mentioned

$HTFL

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$HTFLNeutralLow

Why it matters

The newest fact is the disclosed sale size, price, and post-transaction share count, which can influence short-term sentiment but does not change fundamentals by itself.

Market read

Insider selling under a 10b5-1 plan is typically a low-signal event; any trading impact is likely modest and short-lived.

What to watch

Traders may over-weight insider sales; without accompanying guidance, trial, or contract updates, the signal is usually weak.

Relevance 4/10Novelty 3/10Timing: filed after-hours on 2026-08-12, covering a sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Heartflow, Inc. (HTFL).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HTFLNeutralMedium confidence

Context

Heartflow CEO Farquhar John C.M. sold 22,562 shares at $28.31 under a 10b5-1 plan, reducing direct holdings to 436,280.

Expected impact

Likely limited, with any reaction more sentiment-driven than fundamentals-driven.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 open-market sale; the filing provides timing and size, but no new company-specific operational or financial information.

Market effects

Sector

Minimal; insider sale in a single healthcare/medical device name does not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish information.

Key entities

issuer
Heartflow, Inc.
Company whose CEO insider sale is disclosed on Form 4.
insider
Farquhar John C.M.
CEO and director who sold 22,562 shares at $28.31 under a 10b5-1 plan.

Read at source ← All news

Med

HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow reported revenue growth outpacing expenses, narrowing operating losses. The company has $253M in cash and expects to achieve positive cash flow by mid-2028. It aims for an 85% non-GAAP gross margin and is expanding its platform with new products like PCI Navigator. Management highlights structural advantages and growing clinical evidence.

finance.yahoo.comNov 14

Med

Canaccord Genuity maintains HeartFlow at Buy, raises price target to $69 from $56

Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.

tradingview.comNov 13

High

Stifel maintains HeartFlow at Buy, raises price target to $70 from $45

Stifel upgraded its price target for HeartFlow to $70 from $45, a 55.6% increase, implying 16.8% upside from the Nov 12 close of $59.92. The firm maintained its Buy rating on the company.

tradingview.comNov 13

$HTFLMed

Stifel raises HeartFlow stock price target to $70 on strong growth

Stifel raised its price target on HeartFlow (NASDAQ:HTFL) to $70 from $45, citing strong Q3 2026 results. Revenue was $72.9M, beating estimates and showing 57% YoY growth. The company raised its full-year revenue guidance to $262M-$264M. Shares are near a 52-week high, up 106% YTD, but some analysts consider the stock overvalued.

investing.comNov 13

$HTFLHighAI 8/10

HeartFlow (HTFL) Q3 2026 Earnings Call Transcript

HeartFlow (HTFL) reported Q3 2026 revenue of $72.9M, up 57% YoY, driven by Plaque adoption and FFRCT utilization. They raised full-year revenue guidance to $262M-$264M, up 49%-50% YoY. Non-GAAP gross margin guidance was increased to 82.5%, with midterm profitability goals reaffirmed. Commercial adoption and clinical evidence support growth.

finance.yahoo.comNov 13

$HTFLMedAI 8/10

What Heartflow (HTFL) Said on Its Q3 Earnings Call

Heartflow (HTFL) expects to reach cash flow profitability by mid-2028, with declining operating expenses and narrowing losses. The company anticipates 1,300 Plaque Analysis-activated accounts by year-end and 37% year-over-year FFRct volume growth in Q4. Plaque Analysis pricing is expected to be flat sequentially, with a 10% increase in Q1 2027. Clinical data shows Plaque Analysis reduces major cardiovascular events and heart attack rates.